Prelude Therapeutics (PRLD) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jun, 2026Opening remarks and agenda
The meeting was called to order by the CEO, who also served as Chairperson, with introductions of key officers and external representatives.
Procedures for voting and meeting conduct were outlined, ensuring an orderly process.
Shareholder proposals
No shareholder proposals were received in accordance with advance notice provisions.
Board and executive committee updates
Three Class III directors were nominated for election to serve three-year terms through the 2029 annual meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Prelude Therapeutics
- KAT6A selective degraders and DAC technology drive innovation, with clinical proof-of-concept expected by 2027.PRLD
Goldman Sachs 47th Annual Global Healthcare Conference 202610 Jun 2026 - Precision oncology pipeline advances with novel JAK2, KAT6A, and CALR-targeted therapies.PRLDJefferies Global Healthcare Conference 20263 Jun 2026
- Net loss narrowed to $10.4M, with cash runway extended into Q2 2028 after $90M raise.PRLDQ1 202612 May 2026
- Advancing first-in-class JAK2V617F and KAT6A therapies with strong clinical and financial momentum.PRLDCorporate presentation12 May 2026
- Annual meeting covers director elections, auditor ratification, and executive pay votes.PRLDProxy filing29 Apr 2026
- Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.PRLDProxy filing29 Apr 2026
- Advancing first-in-class targeted therapies for cancer with strong clinical and financial momentum.PRLDCorporate presentation22 Apr 2026
- Pipeline prioritizes JAK2V617F, KAT6A, and CALR programs, with strong funding through 2027.PRLDConference10 Mar 2026
- Pipeline advances in JAK2V617F and KAT6A programs drive innovation and financial strength.PRLDCorporate presentation10 Mar 2026